To the Editor,

 {#jmv26077-sec-0010}

Currently, coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a public health crisis, with almost five million people have been infected and of which more than 300 000 died.[^1^](#jmv26077-bib-0001){ref-type="ref"} Older ages and several comorbidities, such as hypertension, diabetes mellitus, and cardiovascular diseases, are identified as risk factors for developing severe COVID‐19 and deaths.[^2^](#jmv26077-bib-0002){ref-type="ref"}, [^3^](#jmv26077-bib-0003){ref-type="ref"} It is estimated that 40 million people worldwide have human immunodeficiency virus (HIV) infection.[^4^](#jmv26077-bib-0004){ref-type="ref"} Thus, we are expecting to encounter a significant number of patients with HIV with SARS‐CoV‐2 infection. However, there is limited evidence regarding the impact of HIV infection on the severity and mortality related to COVID‐19. Several case reports and case series showed that the mortality and severity of COVID‐19 were not increased in patients with HIV.[^5^](#jmv26077-bib-0005){ref-type="ref"}, [^6^](#jmv26077-bib-0006){ref-type="ref"}, [^7^](#jmv26077-bib-0007){ref-type="ref"} In contrast, HIV/SARS‐CoV‐2 coinfected patients may have mortality benefits from the immunosuppressive state.[^8^](#jmv26077-bib-0008){ref-type="ref"} However, the data from our institution showed contradictory results. Herein, we presented the case series of hospitalized HIV patients with COVID‐19 in a single hospital in the South Bronx, the area that is well known for its most poverty, least education, highest criminal, and poorest health outcomes in New York. The clinical features and outcomes of nine HIV/SARS‐CoV‐2 coinfected patients admitted to our hospital from 25 March to 20 April 2020 are discussed.

Table [1](#jmv26077-tbl-0001){ref-type="table"} provides demographic data, clinical features, and outcomes of each patient. The median age of the patients was 58 years old (range, 31‐76). Seven were males and two were females. All patients had multiple comorbidities. The diagnosis of COVID‐19 was confirmed by a positive SARS‐CoV‐2 RT‐PCR test from nasopharyngeal swab specimens. Most recent patients CD4+ T cell count ranged from 179 to 1827 per mm^3^. HIV viral load was very low to undetectable. Eight patients were on highly active antiretroviral therapy (HAART), of which six reported medication compliances. HAART was discontinued during hospital admission in four patients, two of which was due to acute kidney injury (AKI), and the other two were for an unclear reason. Fever, cough, and dyspnea were the most common presenting symptoms among all patients. One patient initially presented with gastrointestinal tract symptoms, including nausea, vomiting, and watery diarrhea. Chest X‐ray (CXR) abnormalities compatible with COVID‐19 pneumonia were found in eight patients (89%) and correlated with disease severity. All patients\' blood cultures were negative. Seven patients eventually died (78%), of which four due to hypoxemic respiratory failure and three from septic shock and multiorgan failures.

###### 

Described demographic data, clinical features, and outcomes of each patient

  Patient                 1                            2                                  3                                         4                                  5                                         6                                         7                                      8                                          9
  ----------------------- ---------------------------- ---------------------------------- ----------------------------------------- ---------------------------------- ----------------------------------------- ----------------------------------------- -------------------------------------- ------------------------------------------ ------------------------------------------
  Demographic data                                                                                                                                                                                                                                                                                                                           
  Age/sex                 37/male                      31/male                            70/male                                   76/female                          63/male                                   52/male                                   58/male                                52/male                                    76/female
  Other comorbidities     Tertiary syphilis, HCV       Obesity, HLD                       HTN, HLD, AF, HF, HCV, COPD               HIV, DM                            HTN                                       DM                                        HTN, DM, HLD, COPD                     HCV, HLD, COPD, HTN                        HTN, COPD, AF, pulmonary HTN
  Recent CD4 counts       425                          636                                1827                                      698                                243                                       504                                       179                                    Unknown                                    420
  Recent HIV RNA          \<20                         Not detect                         Not detect                                \<30                               \<30                                      31                                        Not detect                             Unknown                                    Not detect
  HAART ‐regimen          FTC, TAF, DTG, RTV, DRV      EVG, FTC, TAF, cobicistat          FTC, TDF, RAL                             FTC, TAF, ATV, cobicistat          FTC, TAF, DTG                             EVG, FTC, TAF, cobicistat                 Not‐taking                             FTC, TDF, DTG                              EFV, FTC, TAF
  HAART ‐compliance       Noncompliance                Compliance                         Compliance                                Compliance                         Compliance                                Noncompliance                             Not‐taking                             Compliance                                 Compliance
  Clinical Presentation                                                                                                                                                                                                                                                                                                                      
  Presenting symptoms     Cough, myalgia, rhinorrhea   Dyspnea, cough, fever              Dyspnea                                   Cough, fever                       Watery diarrhea, vomiting, fever          Dyspnea                                   Dyspnea, cough, fever                  Dyspnea, cough                             Dyspnea, cough
  Vital signs             Normal                       Remarkable for HR 126, T 38.7      Remarkable for HR 160 (AF), RR 30         Remarkable for T 38.9              Remarkable for T 38.2                     Remarkable for HR 126, RR 30              Remarkable for HR 116, RR 32, T 39.3   Remarkable for HR 106, RR 25               Remarkable for T 38, RR 27
  SpO~2~                  100                          95                                 70%                                       88%‐90%                            95%                                       75%                                       85%                                    96%                                        82%
  CXR                     Normal                       Bilateral multifocal infiltrates   Bilateral ground glass opacities          Bilateral ground glass opacities   Bilateral ground glass opacities          Bilateral ground glass opacities          Bilateral interstitial infiltrates     Bilateral multifocal infiltrates           Bilateral multifocal infiltrates
  WBC                     3950                         5520                               12,830                                    4970                               5010                                      12 890                                    7780                                   1090                                       4000
  \% Lymphocytes          46.6%                        15.9%                              9.4%                                      22.7%                              34.3%                                     15.7                                      10.4                                   10.1                                       17.3
  Inflammatory markers    CRP 0.25, DD 307, FER 56     CRP 7.8, DD \<177                  IL6 213, FER 293                          CRP 11, DD 265, FER 937 IL6 85     CRP 4, FER 884                            CRP 37, DD 37 946, FER 1010 IL6 251       CRP 34, DD 329, IL6 100                DD 714                                     CRP 3.7, DD 407, FER 240, IL6 50
  Hospital courses                                                                                                                                                                                                                                                                                                                           
  HAART changes           No change                    No change                          Not given                                 Not given                          No change                                 No change                                 Not given                              Not given                                  FTC, TAF
  COVID‐19 treatment      Symptomatic                  Symptomatic                        HCQ                                       HCQ                                HCQ                                       None                                      HCQ                                    None                                       None
  Antibiotics             None                         None                               Cef‐3, AZ                                 Cef‐3                              Cef‐3, AZ                                 None                                      Cef‐3, AZ                              Tazocin, doxy                              AZ
  Highest PEEP            Not intubated                Not intubated                      14                                        20                                 14                                        10                                        20                                     Not intubated                              Not intubated
  LOS, d                  1                            3                                  12                                        7                                  13                                        1                                         14                                     3                                          5
  Outcome                 Symptoms resolve             Symptoms resolve                   Death due to septic shock from COVID‐19   Death due to ARDS from COVID‐19    Death due to septic shock from COVID‐19   Death due to septic shock from COVID‐19   Death due to ARDS from COVID‐19        Death due to hypoxemic RSF from COVID‐19   Death due to hypoxemic RSF from COVID‐19

Abbreviations: AF, atrial fibrillation; ATV, atazanavir; AZ, azithomycin; Cef‐3, ceftriaxone; COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease‐2019; CRP (mg/dL), C‐reactive protein; CXR, chest X‐ray; DD (ng/mL), D‐dimer; doxy, doxycycline; DRV, darunavir; DTG, dolutegravir; EVG, elvitegravir; EFV, efavirenz; FER (mg/dL), ferritin; FTC, emtricitabine; HCV, hepatitis C infection; HCQ, hydroxychloroquine; HF, heart failure; HLD, hyperlipidemia; HTN, hypertension; IL6 (pg/mL), interleukin‐6; LOS, length of stay; PEEP, positive end‐expiratory pressure; RAL, raltegravir; RSF, respiratory failure; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; WBC, white blood cells.
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Recent evidence demonstrated that several clinical features, including older age, lymphopenia, elevated inflammatory markers, and CXR abnormalities are predictive factors for severe COVID‐19 and death.[^2^](#jmv26077-bib-0002){ref-type="ref"}, [^3^](#jmv26077-bib-0003){ref-type="ref"}, [^9^](#jmv26077-bib-0009){ref-type="ref"} We found a similar pattern in HIV/SARS‐CoV‐2 coinfected patients. Also, typical CXR abnormalities representing COVID‐19 pneumonia were similar among all HIV patients regardless of their CD4 count.

Compare to previous studies[^5^](#jmv26077-bib-0005){ref-type="ref"}, [^6^](#jmv26077-bib-0006){ref-type="ref"}, [^7^](#jmv26077-bib-0007){ref-type="ref"}; our patients had significantly lower CD4+ cells count but showed a higher mortality rate. The inverse relationship between CD4+ cell count and mortality rate contradicts the hypothesis that HIV/SARS‐CoV‐2 coinfected patients have favorable prognoses because of paradoxical prevention from robust cytokine storms due to their immunosuppressive states and HIV‐related lymphopenia.[^8^](#jmv26077-bib-0008){ref-type="ref"} Moreover, the extremely high mortality rate observed in our case series raises the concern that HIV infection and low CD4+ cell counts may negatively impact on COVID‐19 outcomes.

It was clear from our case series that immunocompromised state from HIV‐related lymphopenia, unfortunately, cannot prevent against progression to severe COVID‐19 and death, as opposed to B‐cell suppression in some specific population, such as patients taking B‐cell depleting medication.[^8^](#jmv26077-bib-0008){ref-type="ref"}, [^9^](#jmv26077-bib-0009){ref-type="ref"}, [^10^](#jmv26077-bib-0010){ref-type="ref"}, [^11^](#jmv26077-bib-0011){ref-type="ref"} We proposed two possible explanations. First, host immunity response to SARS‐CoV‐2 requires T lymphocytes. HIV‐related lymphopenia, therefore, delay the clearance of viruses and promote the progression of the disease. Second, the key pathogenesis of cytokines storms in severe COVID‐19 may stem from the dysregulation of B lymphocytes so that HIV‐related T‐cell suppression does not confer any protective role against severe COVID‐19.

Our report had several limitations. First, the results were based on only nine patients. Second, all patients had several comorbidities that negatively impact the COVID‐19 prognoses. Thus, further large observational studies are needed to verify our results. Understanding the clinical course and mechanism of COVID‐19 in patients with HIV will help elucidate the pathogenesis of SARS‐CoV‐2 infection and the progression to severe disease, which will help in better management and prevention of COVID‐19 in HIV patients and perhaps in general.
